Topic 4
Gene therapy for ADA deficiency
Gene therapy treats a disease by putting a working gene into a person's cells, to make up for a gene that does not work. The first clinical gene therapy was given in 1990 to a 4-year-old girl with adenosine deaminase (ADA) deficiency.
ADA is an enzyme the immune system needs in order to work. The disorder is caused by a deletion of the gene for ADA. Some children are cured by bone marrow transplantation; others are treated by enzyme replacement therapy, in which working ADA is given by injection. Neither approach is completely curative.
Predict first
In gene therapy for ADA deficiency, the patient's own lymphocytes get a working ADA gene and are put back. Why must this be repeated from time to time?
Lymphocytes are taken from the patient's blood and grown in a culture outside the body.
Text version
- Lymphocytes are taken from the patient's blood and grown in a culture outside the body.
- A functional ADA cDNA is put into the lymphocytes using a retroviral vector.
- The lymphocytes, now carrying a working ADA gene, are returned to the patient.
- The treated lymphocytes are not immortal. As they die their number falls, so fresh treated cells must be infused periodically.
A permanent cure would need the gene in cells that keep dividing. If a working ADA gene, isolated from marrow cells that produce ADA, were put into cells at an early embryonic stage, it could be a permanent cure.
Compare the treatments
What is done
ADA cDNA is put into the patient's lymphocytes with a retroviral vector.
Outcome
Not permanent: the cells are not immortal, so infusions are repeated.